Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and Food Effect Study of ABBV-932
NCT05738850Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-932 in generalized anxiety disorder (GAD) (7 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration of ABBV-932 at 5 days, Time to Cmax of ABBV-932 at 5 days and 6 more. Started Feb 2023; status: completed.
02
Drugs
ABBV-932
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT05738850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738850.